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Abstract 
 
The PI3K signaling cascade, a key mediator of cellular survival, growth and metabolism, is 
frequently altered in human cancer. Activating mutations in PIK3CA, which encodes the alpha 
catalytic subunit of PI3K, occur in ~30% of breast cancers. These mutations result in constitutive 
activity of the enzyme and are oncogenic but it was not known whether they are sufficient to 
induce mammary carcinomas in mice. In this work, we generated mice conditionally expressing 
mutant PIK3CA H1047R in the luminal mammary epithelium targeted by either an MMTV or a 
WAP promoter. We demonstrated that expression of PIK3CA H1047R evokes heterogeneous 
tumors that express luminal and basal markers and are positive for the estrogen receptor. 
Additionally, we showed that such PIK3CA H1047R expression leads to a dramatic delay in 
mammary gland involution and that parity accelerates PIK3CA H1047R-induced carcinogenesis. 
Our results suggest that the PIK3CA H1047R oncogene targets a multipotent progenitor cell and 
show that this model recapitulates features of human breast tumors with PIK3CA H1047R. 
We further showed that WAP targeted expression of another PIK3CA mutant, E545K, 
also induces mammary tumors, albeit with a longer tumor latency. Interestingly, luminal 
expression of wild type PIK3CA does not result in tumor formation, demonstrating that the in 
vivo tumorigenicity of mutant PIK3CA is caused by the mutation rather than overexpression. 
Expression of PIK3CA mutations in all cells of the mouse leads to premature death. The 
mice develop multiple hematomas underneath the skin once they express mutant PIK3CA, 
however, no defect in the blood coagulation cascade or platelets was discovered and the exact 
cause of death remains unknown. 
Mammary epithelial cells (MEC) from PIK3CA mutant mice had enhanced sphere-
forming capacity with respect to both, size and frequency. In addition, when transplanted into a 
cleared fat pad, H1047R mutant epithelial cells partially reconstitute the gland and form 
hyperplasias that progress to carcinomas. 
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Introduction 
1. The Mammary Gland 
1.1 Mammary gland development and physiology 
Since the human breast is not readily accessible for research only little is known about human 
breast development (Howard and Gusterson 2000). Therefore, much of our knowledge about 
mammary gland biology comes from extensive studies on the mouse mammary gland which is 
thought to be regulated by growth patterns and control mechanisms comparable to those of 
the human breast (Cardiff and Wellings 1999). A unique feature of the mammary gland with 
respect to other organs is the fact that much of its developmental processes occur postnatally 
during puberty and later during reproductive cycles. 
After birth the mammary epithelium consists of a rudimentary ductal tree embedded in 
a stromal environment called the mammary fat pad. With the onset of puberty and the 
secretion of the ovarian hormones estrogen and progesterone, the tips of this rudimentary 
ductal system enlarge forming specialized structures called terminal end buds (TEB) which 
further branch and fill the mammary stroma. TEBs are highly proliferative and a monolayer of 
stem cells within the cap cells of the TEBs gives rise to the two major cell types of the bi-layered 
mammary gland epithelium. Luminal epithelial cells form the inner layer and secrete milk 
during lactation. The luminal cells are surrounded by contractile myoepithelial cells which 
squeeze the secreted milk (Silberstein 2001). 
During pregnancy several hormones including progesterone and prolactin induce 
massive tissue remodeling characterized by ductal branching and extensive cell proliferation to 
form the alveoli, the functional units of the mammary gland which secrete milk. By the end of 
pregnancy the mammary epithelium fills out the whole mammary fat pad (Silberstein 2001; 
Oakes, Hilton et al. 2006). After lactation the mammary gland undergoes tissue remodeling 
called involution, during which the secretory alveoli collapse and massive epithelial cell death 
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occurs while the adipocytes gradually increase in volume (Watson 2006). The involuted 
mammary gland resembles that of a virgin mouse and is ready to go through another 
reproductive cycle. 
 
1.2 The mammary gland cell hierarchy 
Adult stem cells have the capability to produce all the cell types of a given organ. In the 
mammary gland adult stem cells have been described by their ability to reconstitute a 
functional gland when donor mammary tissue fragments or even a single cell was transplanted 
into an epithelium-free fat pad (Deome, Faulkin et al. 1959; Kordon and Smith 1998; 
Shackleton, Vaillant et al. 2006; Stingl, Eirew et al. 2006; Sleeman, Kendrick et al. 2007). 
Transplantation experiments led to the identification of cells capable of forming either 
ductal- or lobule-limited outgrowths. While lobuloalveolar progenitors lack cap cells at the tip 
of TEBs and are therefore unable to penetrate the fat pad, ductal progenitors fill the fat pad but 
fail to undergo lobuloalveolar development during pregnancy (Kordon and Smith 1998; Bruno 
and Smith 2010). 
The combination of cell surface markers and fluorescence-activated cell sorting (FACS) 
technology has led to the identification and isolation of distinct mammary epithelial cell 
subpopulations. Based on the expression levels of the heat stable antigen (CD24) the cells of 
the mammary gland can be separated into CD24high, CD24med, and CD24neg cells. The CD24high 
cell population is enriched in luminal cells and therefore stains almost exclusively for the 
luminal marker cytokeratin 18 (K18) (Sleeman, Kendrick et al. 2006). The CD24high cells can 
further be resolved into two subpopulations based on their expression levels of the stem cell 
antigen 1 (Sca-1). CD24 positive cells expressing Sca-1 (CD24high/Sca-1+) are enriched in luminal 
cells expressing the estrogen receptor (ER) and do not have mammary gland repopulating 
activity. In contrast, the CD24high/Sca-1- cells are mostly ER negative and have potent colony 
forming activity in vitro and limited mammary gland repopulating activity in vivo (Sleeman, 
Kendrick et al. 2007). The cell population expressing moderate levels of CD24 (CD24med/low) 
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stains mostly positive for the basal marker cytokeratin 14 (K14) but negative for K18 and 
contains basal epithelial cells. These can be further resolved based on the levels of β1-integrin 
(CD29) or α6-integrin (CD49f) in a stem cell enriched population and in a population containing 
mainly myoepithelial cells. The stem cell enriched population is characterized by high 
expression levels of CD29, high levels of CD49f, moderate levels of CD24, and the absence of 
Sca-1 (Shackleton, Vaillant et al. 2006; Sleeman, Kendrick et al. 2006; Stingl, Eirew et al. 2006). 
The CD24med/low cells expressing low levels of CD29/CD49f are mainly myoepithelial cells. The 
CD24neg population contains non-epithelial cells (Sleeman, Kendrick et al. 2006). 
 
Figure 1. FACS-based separation of mammary epithelial cells into distinct subpopulations. Using the cell surface 
marker CD24, cells from the mammary gland can be separated into three populations: CD24neg, CD24low, and 
CD24high. The CD24neg cells are stromal cells while the CD24low and CD24high cells are epithelial cells. The CD24high 
cells are luminal epithelial cells and can be further separated into a Sca-1+ population (enriched in ER+ cells) and a 
Sca-1- population (enriched in ER- cells). Based on their CD49f expression, the CD24low cells which are basal 
epithelial cells can be further separated into myoepithelial cells (CD49flow) and a mammary stem cell enriched 
population (CD49fhigh). 
 
2. Breast Cancer 
2.1 Breast cancer prevalence 
Breast cancer is by far the most common form of cancer in women and accounts approximately 
for 23% of all cancers in women worldwide. In absolute numbers, in the year 2008, an 
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estimated 1’384’000 new breast cancer cases occurred while the disease accounted for roughly 
458’000 deaths worldwide (World Health Organization). 
 
2.2 Breast cancer classification 
Breast cancer is a heterogeneous disease both histologically and molecularly. Efforts have been 
made in the past decades to classify breast cancers into different subtypes which would allow 
patient prognosis and prediction of optimal treatment. Historically, human breast cancers were 
grouped into approximately 18 different subtypes based on histological features (Stingl and 
Caldas 2007), however, the prognostic and predictive value of this classification is very limited 
(Sims, Howell et al. 2007). Of a better clinical value is the status of ER, progesterone receptor 
(PR), and the epidermal growth factor receptor 2 (HER2/ErbB2) which has direct impact on 
treatment strategies. 
Global gene expression profiling of breast cancer has led to the identification of at least 
six distinct and reproducible subtypes: luminal A, luminal B, ErbB2-enriched, basal, normal-like, 
and claudin-low (Perou, Sorlie et al. 2000; Sorlie, Perou et al. 2001; Sorlie, Tibshirani et al. 2003; 
Sotiriou, Neo et al. 2003; Herschkowitz, Simin et al. 2007; Perou and Borresen-Dale 2011). 
Notably, patients with luminal A breast cancer have the best prognosis (Sorlie, Tibshirani et al. 
2003). 
The luminal subtypes are characterized by the expression of luminal cytokeratins and 
genes typical for luminal cells of the normal mammary gland (e.g., K8/18, K19, CD24, Mucin1, 
and GATA3) (Rakha, El-Sayed et al. 2007) as well as expression of the hormone receptors ER 
and/or PR (Rouzier, Perou et al. 2005; Hu, Fan et al. 2006; Sotiriou and Pusztai 2009). The 
luminal subtypes A and B can be discriminated based on tumor grade, genomic grade and 
patient outcome. Breast tumors of the luminal subtype A are typically of lower tumor grade, 
have a lower genomic grade, and correlate with improved patient survival compared to those 
of luminal subtype B (Sorlie, Tibshirani et al. 2003; Sotiriou, Neo et al. 2003; Loi, Haibe-Kains et 
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al. 2007; Sotiriou and Pusztai 2009). Further, luminal A tumors are sensitive to endocrine 
therapy whereas those of luminal B subtype show incomplete sensitivity to endocrine therapy 
(Sotiriou and Pusztai 2009). 
The ErbB2-enriched molecular subtype of breast cancer is typically characterized by 
elevated expression of ErbB2 and accounts for ~10% of breast cancers (Perou and Borresen-
Dale 2011). Another ~10% of breast cancers are clinically defined ErbB2-positive breast cancers 
that co-express ER and fall into the luminal subtypes (typically luminal B) (Sotiriou and Pusztai 
2009; Perou and Borresen-Dale 2011). ErbB2-enriched tumors are generally of higher tumor 
grade than luminal tumors (Sotiriou and Pusztai 2009) and correlate with a bad prognosis 
(Sorlie, Perou et al. 2001; Sorlie, Tibshirani et al. 2003; Hu, Fan et al. 2006). Elevated levels of 
surface ErbB2 result in the formation of homodimers and heterodimers with other receptor 
tyrosine kinases of the human epidermal growth factor receptor (HER) family including 
epidermal growth factor receptor 1 (EGFR) and 3 (ErbB3) (Graus-Porta, Beerli et al. 1997; Hynes 
and Lane 2005). ErbB2 and ErbB3 form a potent tumorigenic heterodimer and activate key 
signaling cascades including the mitogen-activated protein kinase (MAPK) and phosphoinositol-
3-kinase (PI3K) pathway (Holbro, Beerli et al. 2003; Hynes and Lane 2005). Some of the ErbB2 
positive tumors are sensitive to trastuzumab, an antibody targeting the extracellular domain of 
ErbB2 which is used in combination with chemotherapy as the gold standard treatment for 
metastatic ErbB2 positive breast cancer (Hynes and Lane 2005; Nahta and Esteva 2006). 
Breast tumors of the basal-like subtype are less frequent than those of the luminal or 
ErbB2 positive subtype and correlate with a very aggressive disease although they can be 
particularly sensitive to chemotherapy (Rouzier, Perou et al. 2005). Some basal-like tumors 
express high levels of basal cytokeratins like K5 and growth factor receptors including EGFR and 
c-Kit. However, most of the basal-like tumors lack expression of ER, PR, and ErbB2 and are 
therefore also called triple negative (TN) tumors (Sotiriou and Pusztai 2009). A characteristic 
feature of basal-like carcinomas is the dysfunction of BRCA1, a gene involved in DNA repair and 
chromosomal stability (Turner, Reis-Filho et al. 2007; Sotiriou and Pusztai 2009). Sporadic basal-
like tumors display BRCA1 promoter methylation and/or transcriptional inactivation (Turner, 
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Tutt et al. 2004; Turner, Reis-Filho et al. 2007). BRCA1 germ line mutations correlate with 
increased breast cancer susceptibility and a link between hereditary BRCA1-associated tumors 
and the basal-like subtype has been described (Easton, Ford et al. 1993; Foulkes, Stefansson et 
al. 2003). 
 
3. PI3K Signaling 
 
The phosphatidylinositol 3-kinase (PI3K) pathway is often subverted during neoplastic 
transformation (Engelman, Luo et al. 2006) and provides cancer cells with a competitive 
advantage by decreasing cell death and increasing cell proliferation, migration, invasion, 
metabolism, angiogenesis, and resistance to chemotherapy. Mechanisms of activation of the 
PI3K pathway in cancer include the loss of expression or rare mutation of the PTEN 
phosphatase that reverses PI3K action (Rhei, Kang et al. 1997; Ueda, Nishijima et al. 1998; 
Perren, Weng et al. 1999; Depowski, Rosenthal et al. 2001; Perez-Tenorio, Alkhori et al. 2007), 
the activation downstream of oncogenic receptor tyrosine kinases, the mutation/amplification 
of Akt, and the mutation and/or amplification of PIK3CA. 
 
3.1 PI3K classification 
PI3Ks are lipid kinases that phosphorylate different phosphatidylinositols (PI) at the 3’ position 
of the inositol ring. There are three classes of PI3K based on their substrate preferences and 
domain structure. 
Class I PI3Ks preferentially phosphorylate PI-4,5-bisphosphate (PI-4,5-P2 or PIP2) to 
generate PI-3,4,5-trisphosphate (PI-3,4,5-P3 or PIP3) and are further divided into two 
subfamilies. Class IA PI3Ks are activated by receptor tyrosine kinases (RTKs) in contrast to class 
IB PI3Ks that are activated by G-protein-coupled receptors (GPCRs) (Katso, Okkenhaug et al. 
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2001). In response to extracellular signals class I PI3Ks regulate cell growth, survival, apoptosis, 
protein synthesis, and metabolism. 
Class II PI3Ks preferentially generate PI-3-P but poorly phosphorylate PI-4,5-P2. Class II 
PI3Ks bind to clathrin and regulate clathrin-mediated membrane trafficking and receptor 
internalization (Gaidarov, Smith et al. 2001). Vps34 is the only member of class III PI3K and was 
identified in yeast as a regulator of trafficking vesicles from the Golgi apparatus to the vacuole 
(Odorizzi, Babst et al. 2000). However, relatively little is known about the specific functions of 
class II and III PI3K. 
 
 
Figure 2. The classification and molecular architecture of PI3Ks. The architecture of the catalytic and adaptor 
subunits of class I PI3Ks and the domains of class II and III PI3Ks are shown. The dashed lines represent the 
extended N-terminal region that exists in the long adaptor subunits p85α and p85β but is absent in the shorter 
p55α/p50α and p55γ forms. The p85 binding domain (green) of class IA catalytic subunits is referred to as adaptor 
binding domain (ABD) in the text. BH: breakpoint cluster region homology, PIK: phosphatidylinositol kinase 
homology, SH2: Src-homology 2 domain, SH3: Src-homology 3 domain, Adapted from (Engelman, Luo et al. 2006). 
 
3.2 Structure of class I PI3Ks 
Class IA PI3Ks occur as heterodimers consisting of a p110 catalytic and a p85 regulatory subunit. 
There are three highly homologous catalytic isoforms p110α, p110β, and p110δ, which are 
encoded by the three genes PIK3CA, PIK3CB, and PIK3CD. The class IA catalytic proteins contain 
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an N-terminal adaptor binding domain (ABD) which interacts with the regulatory subunits, a 
Ras-binding domain (RBD) which enables interaction with the small GTPase Ras, a C2 domain, 
the helical domain, and a C-terminal kinase domain. 
Class IA catalytic subunits bind to a total of five different regulatory subunits encoded by 
three genes. PIK3R1 encodes p85α as well as to the two shorter proteins p55α and p50α. p85β 
and p55γ are encoded by PIK3R2 and PIK3R3, respectively. All regulatory isoforms share a 
common p110-binding domain or inter-SH2 (Src-homology 2) domain flanked by two SH2 
domains. The two longer isoforms p85α and p85β further contain an N-terminal Src-homology 
3 (SH3) domain and a breakpoint cluster region (BCR) homology (BH) domain flanked by two 
proline-rich regions (Fruman, Meyers et al. 1998; Engelman, Luo et al. 2006). 
 
3.3 The growth factor receptor/PI3K/Akt signaling axis 
In its inactive state the regulatory subunit p85 keeps the kinase activity of the catalytic subunit 
p110 at a low activity state via an intermolecular interaction of the N-terminal SH2 domain of 
p85 with the helical domain of p110 (Yu, Zhang et al. 1998). As mentioned above class IA PI3Ks 
are activated by upstream receptor tyrosine kinases (RTK) including the insulin receptor (IR), 
the insulin-like growth factor 1 receptor (IGF-1R), the platelet-derived growth factor receptor 
(PDGFR), and members of the epidermal growth factor receptor (EGFR) family. Binding of the 
respective ligands induces receptor dimerization resulting in receptor autophosphorylation. 
Phosphorylated tyrosine residues within the cytoplasmic domain of these receptors or within 
adaptor molecules like the insulin receptor substrate (IRS) 1 and 2 recruit the regulatory 
subunit p85 via its SH2 domains. Binding of the SH2 domain of p85 to phosphotyrosine residues 
relieves the inhibition of p110 and mediates translocation of the catalytic subunit to the plasma 
membrane (Okkenhaug and Vanhaesebroeck 2001). Interaction with the GTP-bound form of 
the RAS protein further increases PI3K kinase activity (Rodriguez-Viciana, Warne et al. 1994; 
Rodriguez-Viciana, Warne et al. 1996) 
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Activated PI3K converts PIP2 into PIP3, a reaction which is reverted by the tumor 
suppressor phosphatase and tensin homolog deleted on chromosome ten (PTEN) (Maehama, 
Taylor et al. 2001; Wishart and Dixon 2002). PIP3 recruits proteins containing a pleckstrin 
homology (PH) domain including the downstream molecules 3-phosphoinositide-dependent 
kinase 1 (PDK1) and Akt (Corvera and Czech 1998). Upon autophosphorylation, PDK1 
phsophorylates the serine-threonine kinase Akt on Thr 308 (Alessi, James et al. 1997). In 
addition, and dependent on the physiological context, Akt is phosphorylated at the 
hydrophobic motif on Ser 473 by the mammalian target of rapamycin (mTOR)/rictor complex or 
DNA-dependent protein kinase (DNA-PK) which results in full Akt activation (Sarbassov, Guertin 
et al. 2005; Bozulic, Surucu et al. 2008). Akt is a key effector of PI3K-mediated signaling 
regulating a myriad of downstream targets and cellular responses (Figure 3). 
 
Figure 3. The PI3K/Akt signaling pathway regulates a myriad of downstream targets and cellular responses. The 
PI3K/Akt and related pathways are key effectors of receptor tyrosine kinases. Activation of membrane kinases 
including the epidermal growth factor receptor (EGFR) by external growth factors initiates receptor dimerization 
and activates these intracellular pathways. Akt is activated downstream of PI3K and has multiple targets including 
MDM2, NF , FKHR, BAD, GSK3β, and mTOR to regulate cell cycle, apoptosis, metabolism, growth, and translation. 
Adapted from (Hennessy, Smith et al. 2005). 
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3.4 PI3K signaling mediates cell survival and cell cycle progression 
Akt promotes cell cycle progression by blocking forkhead box (FOXO) transcription factors. Akt 
phosphorylates discrete sites on FOXO proteins resulting in their exclusion from the cell nucleus 
and targeting to proteasomal degradation (Biggs, Meisenhelder et al. 1999; Brunet, Bonni et al. 
1999; Kops, de Ruiter et al. 1999; Takaishi, Konishi et al. 1999; Tang, Nunez et al. 1999; 
Matsuzaki, Daitoku et al. 2003; Plas and Thompson 2003). Inhibition of FOXO results in 
decreased expression of cyclin dependent kinase inhibitors p27kip1 and p21cip1, increased levels 
of cyclin D1 and D2 and a decline in proapoptotic proteins including BIM and FasL (Medema, 
Kops et al. 2000; Dijkers, Birkenkamp et al. 2002; Ramaswamy, Nakamura et al. 2002; Schmidt, 
Fernandez de Mattos et al. 2002; Seoane, Le et al. 2004). Akt negatively regulates levels of the 
tumor suppressor p53 via phosphorylation of MDM2, an E3 ubiquitin ligase, which causes 
degradation of p53 (Zhou, Liao et al. 2001). In contrast to FOXO and p53, PI3K activity results in 
activation of the transcription factor NFκB mediating cell survival and cell proliferation (Bader, 
Kang et al. 2005). Akt can also regulate survival and cell cycle progression by directly 
phosphorylating and inhibiting the proapoptotic protein BAD (Datta, Dudek et al. 1997; del 
Peso, Gonzalez-Garcia et al. 1997) and the cell cycle inhibitor p27kip1 (Liang, Zubovitz et al. 2002; 
Shin, Yakes et al. 2002; Viglietto, Motti et al. 2002). 
 
3.5 PI3K signaling regulates protein synthesis 
Akt phosphorylates the protein tuburin, a member of the tuberous sclerosis complex 2 (TSC2) 
(Inoki, Li et al. 2002; Potter, Pedraza et al. 2002). This event inhibits the GAP (GTPase activating 
protein) activity of the TSC1-TSC2 complex resulting in an increase in the active GTP-bound 
form of its substrate Rheb (small G protein Ras homologue enriched in brain) which in turn 
phosphorylates and activates the mTOR complex 1 (mTOR-raptor complex or mTORC1) 
(Garami, Zwartkruis et al. 2003; Inoki, Li et al. 2003; Zhang, Gao et al. 2003). The mTORC1 in 
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turn phosphorylates the eukaryotic translation initiation factor 4E-binding protein (4E-BP1) and 
p70S6Kinase. On the one hand hyperphosphorylated 4E-BP1 dissociates from the eukaryotic 
translation initiation factor 4E (eIF4E) allowing it to form an active translation initiation complex 
at the 5’ end of mRNA (Ruggero and Sonenberg 2005). On the other hand p70S6Kinase 
phosphorylates the ribosomal protein S6 resulting in increased protein synthesis (Hay and 
Sonenberg 2004; Engelman, Luo et al. 2006).  
 
3.6 PI3K signaling controls metabolism 
Upon growth factor binding, PI3K regulates several processes important for nutrient uptake and 
cell metabolism via its downstream mediator Akt. In insulin-responsive tissues like fat and 
striated muscle, Akt2 is the predominant Akt isoform and activation of Akt2 promotes the 
translocation of the glucose transporter 4 (GLUT4) to the plasma membrane (Engelman, Luo et 
al. 2006; Manning and Cantley 2007). Once glucose is within the cell it can be converted into 
glycogen for storage or enter glycolysis for energy production, two processes in which Akt is 
involved. Akt phosphorylates and inhibits glycogen synthase kinase 3 (GSK3) which prevents it 
from blocking glycogen synthase and thus stimulates glycogen synthesis (Manning and Cantley 
2007). At the same time, in liver, Akt can inhibit gluconeogenesis and fatty acid oxidation 
through direct control of peroxisome proliferator-activated receptor-coactivator 1α (PGC-1α) 
(Li, Monks et al. 2007). 
 
4. The PI3K pathway in normal mammary gland physiology 
4.1 The roles of Akt isoforms in normal mammary gland physiology 
The expression levels of the different isoforms of Akt in the mammary gland differ significantly 
during a reproductive cycle. By the end of pregnancy and throughout lactation, Akt1 is the 
predominant isoform being expressed. With the onset of mammary gland involution Akt1 levels 
drop dramatically. In contrast, Akt2 levels drop by the end of pregnancy and remain low during 
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lactation and early involution. Expression of both isoforms goes back to pre-pregnancy levels by 
the end of involution (day7) (Boxer, Stairs et al. 2006; Maroulakou, Oemler et al. 2008). Unlike 
for Akt1 and Akt2, expression levels of Akt3 do not change much during the reproductive cycle 
of mice (Boxer, Stairs et al. 2006; Maroulakou, Oemler et al. 2008). 
Expression of a constitutively active form of human Akt1 in mice under the control of 
the mouse mammary tumor virus long terminal repeat (MMTV-LTR) caused a dramatic delay in 
mammary gland involution by attenuating cell death (Hutchinson, Jin et al. 2001). Elevated and 
prolonged expression of tissue inhibitor of metalloproteinase-1 (TIMP1) was detected in 
transgenic animals throughout involution. This may contribute to the delay in involution by 
inhibiting matrix metalloproteinases (MMP) such as MMP-3 (Schwertfeger, Richert et al. 2001). 
In addition to delayed involution, a precocious accumulation of lipids during pregnancy and an 
overall increase in the size and number of lipid droplets as well as milk stasis was found in these 
animals. Moreover, the milk fat content was increased in transgenic mice expressing activated 
Akt1 which might be a cause for the lactation defect observed in these animals (Schwertfeger, 
McManaman et al. 2003). Overexpression of wild-type Akt1 under the control of the MMTV 
promoter resulted in a similar delay in involution, however, unlike for activated forms of Akt, 
overexpression of wildtype Akt1 did not evoke neoplasias (Ackler, Ahmad et al. 2002). 
Mice with mammary epithelial cell specific deletion of Akt1 but not Akt2 fail to produce 
sufficient milk. Although the lobuloalveolar development in Akt1 deficient mice appeared 
normal, epithelial cells secreted less milk than in wild-type (Boxer, Stairs et al. 2006) and the 
alveolar structures found in glands of mice with ablated Akt1 were significantly smaller and 
were completely devoid of lipid droplets. Expression of milk proteins such as the whey acidic 
protein (WAP) and β-casein was delayed which correlated with decreased phosphorylation of 
signal transducer and activator of transcription 5a (Stat5a), an important mediator of prolactin-
induced signaling. 
In contrast to AKT1 deletion, AKT2 ablation resulted in enhanced formation of 
lobuloalveolar structures and precocious luminal cell differentiation. Interestingly, the 
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accelerated mammary epithelial differentiation observed in AKT2-null mice is non-cell-
autonomous as transplantation of AKT2-null mammary epithelial cells into wild-type recipient 
mice resulted in normal formation of lobuloalveolar structures and differentiation. This 
observation can be explained by the fact that Akt2 is mainly expressed in stromal cells of the 
mammary gland (Maroulakou, Oemler et al. 2007). Further, the lack of Akt1 caused accelerated 
involution whereas the ablation of AKT2 resulted in a delay in involution. Deletion of AKT3 does 
not have an overt effect on lobuloalveolar differentiation and involution (Maroulakou, Oemler 
et al. 2008). 
 
4.2 The roles of PTEN in normal mammary gland physiology 
MMTV-targeted overexpression of PTEN results in a lactation defect due to a reduced number 
of alveolar epithelial cells, a consequence of reduced proliferation and increased apoptosis 
during pregnancy (Dupont, Renou et al. 2002). Conversely, mammary-specific deletion of both 
PTEN alleles resulted in precocious mammary gland development including increased 
proliferation, excessive side branching, and expression of milk proteins at the virgin state. On 
the other hand, involution was delayed due to an Akt-mediated reduction in apoptotic cells (Li, 
Robinson et al. 2002).  
 
4.3 The effects of p110α on normal mammary gland physiology 
MMTV-mediated expression of myristoylated p110α, which is directed to the plasma 
membrane, resulted in constitutive activation of the PI3K pathway and delayed mammary gland 
involution (Renner, Blanco-Aparicio et al. 2008). In the present work, I found that expression of 
the gain-of-function mutant p110α H1047R (see section 6.1) delayed mammary gland 
involution which is in line with the above mentioned study (Renner, Blanco-Aparicio et al. 
2008). 
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5. PI3K pathway in mammary gland tumorigenesis 
5.1 Akt isoforms in mammary gland tumorigenesis 
Akt1 and Akt2 have different effects on tumorigenesis. In mice that develop tumors due to 
mammary gland specific expression of the viral oncogene polyoma middle T (PymT) uncoupled 
from the PI3K pathway (MTY315/322F), coexpression of active Akt1 severely accelerated tumor 
formation by reducing cell death, but did not affect metastasis (Hutchinson, Jin et al. 2001). In 
mice expressing activated ErbB2 (NDL), constitutively active Akt1 reduced tumor latency, led to 
a more differentiated tumor phenotype, and significantly decreased the number of lung 
metastases (Hutchinson, Jin et al. 2004). Conversely, ablation of AKT1 dramatically delayed 
tumor onset in PymT and ErbB2 transgenic mice (Maroulakou, Oemler et al. 2007). 
In contrast to Akt1, expression of active Akt2 did not affect tumor latency in either PymT 
or in ErbB2 transgenic mice, however, it increased the number of lung metastases (Dillon, 
Marcotte et al. 2009). Conversely, deletion of AKT2 accelerated tumor formation in either 
mouse model (Maroulakou, Oemler et al. 2007). 
Deletion of Akt3 had no overt effect on tumorigenesis in either PymT or ErbB2 
transgenic mice (Maroulakou, Oemler et al. 2007). 
 
5.2 PTEN in mammary gland tumorigenesis 
Mammary-specific deletion of PTEN resulted in mammary epithelial hyperplasia and tumor 
formation eventually (Li, Robinson et al. 2002). Heterozygous deletion of PTEN in mice 
conditionally expressing the oncogene Wnt-1 significantly decreased tumor latency. Notably, in 
the majority of the resulting tumors expression of the remaining wild-type allele was lost. This 
suggests that tumor cells with loss of heterozygosity (LOH) have a growth advantage over cells 
retaining one PTEN allele (Li, Podsypanina et al. 2001). Interestingly, even subtle changes in 
PTEN expression can affect suscebtibility to cancer. Mice bearing a hypomorphic allele of PTEN 
expressed ~20% less PTEN mRNA than wild-type mice, a reduction that was sufficient to induce 
mammary tumors in the majority of animals (Alimonti, Carracedo et al. 2010). In contrast to 
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PTEN deletion, overexpression of PTEN increased tumor latency and decreased tumor growth 
rate in mice expressing oncogenic Wnt-1 (Zhao, Cui et al. 2005). 
Notably, a non cell-autonomous role was demonstrated for PTEN in the formation of 
breast carcinomas. In a recent study, ablation of PTEN in fibroblasts of the mammary gland 
accelerated tumorigenesis. The lack of PTEN caused elevated levels of the transcription factor 
Ets2 and induced genes involved in matrix remodeling and macrophage recruitment (MMP9, 
CCL3) (Trimboli, Cantemir-Stone et al. 2009). 
 
5.3 p110α in mammary gland tumorigenesis 
Expression of myristoylated p110α in mice under the control of the MMTV promoter caused 
morphological changes in mammary ducts of young virgin animals and induced mammary 
carcinomas in ~30% of multiparous females (Renner, Blanco-Aparicio et al. 2008). This 
demonstrates that constitutive activation of p110α results in phenotypes resembling those of 
PTEN loss in vivo (see above). However, this system is artificial and myristoylated p110α does 
not occur in human disease. More recently, we and others (Adams, Xu et al.) generated mice 
conditionally expressing mutant p110α (see section 6.1). These animals form a diverse 
spectrum of mammary carcinomas with 100% penetrance (see section “Results” in this work). 
 
6. PI3K in breast cancer 
6.1 PIK3CA mutations are oncogenic 
Mutations in the gene PIK3CA which encodes for the alpha catalytic subunit of PI3K occur with 
high frequency in several solid carcinomas including those of the colon, breast, brain, and 
stomach (Bachman, Argani et al. 2004; Broderick, Di et al. 2004; Campbell, Russell et al. 2004; 
Samuels, Wang et al. 2004; Lee, Soung et al. 2005; Levine, Bogomolniy et al. 2005). 
Interestingly, the vast majority of mutations in PIK3CA occur at two “hotspots” within the 
coding sequence. Two missense mutations result in the amino acid substitutions E542K and 
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E545K in the helical domain of the protein and another missense mutation leads to the 
substitution H1047R within the kinase domain. 
Expression of the mutant p110α proteins in chicken embryonic fibroblasts (CEFs) was 
transforming and all three mutations increased the lipid kinase activity of the enzyme and 
caused constitutive activity of the PI3K pathway (Kang, Bader et al. 2005). Injection of these 
mutant p110α transformed CEFs into newly hatched chickens induced tumors that showed a 
high degree of vascularization (Bader, Kang et al. 2006). Interestingly the kinase domain 
mutation (H1047R) induced tumors more potently than the helical domain mutations 
(E542K/E545K). Administration of the mTOR inhibitor RAD001 inhibited tumor growth 
suggesting that activation of mTOR signaling is important in mutant p110α-mediated 
tumorigenesis (Bader, Kang et al. 2006). Expression of E545K and H1047R mutant p110α in the 
immortalized but non-transformed mammary epithelial cell line MCF10A increased the PI3K 
kinase activity, allowed epidermal growth factor (EGF)-independent cell growth, anchorage-
independent growth, and disrupted the normal architecture of these cells when grown in 3-
dimensional culture, a phenotype that was mTOR-dependent (Isakoff, Engelman et al. 2005). In 
a cultured human mammary epithelial cell line expressing inactivated p53, hTERT, and high 
levels of c-myc, mutant p110α (E545K, H1047R, myr-PIK3CA) could substitute for the need of 
SV40 largeT antigen for cell transformation (Zhao, Liu et al. 2005). 
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Figure 4. Point mutations in PIK3CA observed in human tumors. Sequencing of the PIK3CA gene in human tumor 
samples revealed somatic point mutations in 38 residues. The mutations localize to various domains of the p110  
primary structure as indicated. 'Hot-spot' mutations are observed at residues E542, E545 and H1047 and are 
highlighted in orange. The figure indicates frequencies of mutation for cancers of the colon, breast, and others, 
which include liver, brain, stomach, lung, and ovary. Adapted from (Bader, Kang et al. 2005). 
 
In contrast to p110δ and p110γ wild-type isoforms, wild type p110α is unable to transform CEFs 
by itself (Kang, Denley et al. 2006). The activation loop of PI3K was shown to determine 
phosphoinositide substrate specificity (Bondeva, Pirola et al. 1998), however substitution of the 
p110α activation loop with that of p110γ and p110δ respectively was not sufficient to render 
p110α oncogenic showing that the activation loop does not determine oncogenicity (Denley, 
Gymnopoulos et al. 2009) among class I PI3Ks. 
Apart from their lipid kinase activity all class I p110 isoforms possess protein serine 
kinase activity (Dhand, Hiles et al. 1994; Lam, Carpenter et al. 1994). However, it was 
demonstrated that it is the lipid kinase activity as well as the lipid product PIP3 that are 
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essential for mutant p110α-mediated transformation (Kang, Denley et al. 2006; Denley, 
Gymnopoulos et al. 2009). 
Rare mutations in p110α also possess the potential to transform cells and to activate 
downstream signaling albeit to a smaller extent than the 3 most common mutations (E542K, 
E545K, H1047R) (Gymnopoulos, Elsliger et al. 2007). 
 
 
6.2 Different mechanisms lead to hyperactivity of p110α hotspot mutants 
Recent genetic and biochemical studies suggest different mechanisms of activation for p110α 
helical and kinase domain mutants. The kinase domain mutant H1047R is thought to trigger a 
conformational shift mimicking the one induced by Ras binding. This model is supported by an 
earlier study demonstrating that Ras binding to p110 induces a conformational change of the 
substrate-binding site (Pacold, Suire et al. 2000) and by mutagenesis experiments in which 
either the p85 binding domain (ABD) or the Ras binding domain (RBD) were deleted. While 
deletion of the ABD completely abolishes the transforming potential of the H1047R kinase 
domain mutant, mutagenesis in the RBD leaves the oncogenic potential of H1047R unaffected 
(Zhao and Vogt 2008). In addition, computational and structural analysis of the H1047R protein 
suggests that the mutation could allow enhanced substrate-to-product turnover (Mankoo, 
Sukumar et al. 2009). Interestingly, although H1047R depends on binding to p85 for 
transforming cells, activation of Akt occurred also in the absence of p85 interaction highlighting 
the importance of additional mechanisms than Akt activation for cellular transformation by 
mutant p110α (Zhao and Vogt 2008). 
In contrast to H1047R, the amino acid substitutions E542K and E545K mimic relief of 
inhibition of p110α upon binding of p85 to growth factor receptors. This model is supported by 
structural data gained from p110α bound to p85 which demonstrates that the charge reversal 
caused by the mutations E542K and E545K disrupts the inhibitory interaction between p85 and 
the helical domain of p110α (Miled, Yan et al. 2007). Further studies showed that mutagenesis 
of the RBD disrupts the oncogenic activity of the helical domain mutants whereas deletion of 
Introduction 
 
 
25 
 
the ABD has no effects on the transforming potential of E542K/E545K demonstrating that 
kinase and helical domain mutants have opposing requirements of either p85 or Ras for their 
oncogenic capacity (Zhao and Vogt 2008). Of note, the kinase activity of H1047R mutated 
p110α could be increased by binding to phosphorylated IRS-1 as a consequence of growth 
factor stimulation similar to the wild type enzyme. In contrast, the activity of E542K and E545K 
mutated molecules was independent of growth factor signaling (Carson, Van Aller et al. 2008). 
 
Figure 5. Mechanism of activation of PIK3CA mutants E542K/E545K. In the wild-type PI3K enzyme, the catalytic 
subunit p110α is kept in a low-activity state via an intramolecular interaction with the regulatory subunit p85 (left). 
Upon binding of the SH2 domains of p85 to phosphorylated tyrosine residues on growth factor receptors, p110α is 
relieved from the inhibitory interaction with p85 and becomes active (center). The glutamate to lysine substitution 
in the helical domain mutants causes a charge reversal which interferes with this inhibitory interaction resulting in 
constitutive active p110α independent of activated growth factor receptors (right). Adapted from (Lee, Engelman 
et al. 2007). 
 
 
6.3 PIK3CA mutations in human breast cancer 
PIK3CA is mutated in ~30% of human breast cancers (Bachman, Argani et al. 2004; Campbell, 
Russell et al. 2004; Samuels, Wang et al. 2004; Lee, Soung et al. 2005; Levine, Bogomolniy et al. 
2005; Saal, Holm et al. 2005; Buttitta, Felicioni et al. 2006; Li, Rong et al. 2006; Maruyama, 
Miyoshi et al. 2007; Gonzalez-Angulo, Stemke-Hale et al. 2009; Kalinsky, Jacks et al. 2009; 
Michelucci, Di Cristofano et al. 2009). Interestingly, the kinase domain mutations are more 
common in breast cancer (~15% of breast cancers) than the helical domain mutations (~10%) 
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(Bachman, Argani et al. 2004; Saal, Holm et al. 2005; Li, Rong et al. 2006; Maruyama, Miyoshi et 
al. 2007; Perez-Tenorio, Alkhori et al. 2007; Lai, Mau et al. 2008; Gonzalez-Angulo, Stemke-Hale 
et al. 2009; Kalinsky, Jacks et al. 2009; Michelucci, Di Cristofano et al. 2009) although some 
studies found similar frequencies of exon 9 and exon 20 mutations (Buttitta, Felicioni et al. 
2006; Barbareschi, Buttitta et al. 2007). This is in contrast to PIK3CA mutation in colorectal 
cancer where the helical domain mutations are predominant (Samuels, Wang et al. 2004). 
Helical domain and kinase domain mutations appear to be mutually exclusive although in rare 
cases tumor samples with double mutants were reported (Saal, Holm et al. 2005). However, it 
could be possible that these rare cases are multiclonal tumors with areas harboring one 
mutation and different areas expressing the other mutation type. PIK3CA mutations and loss of 
PTEN do not seem to be mutually exclusive events although in one report only little overlap 
between mutant PIK3CA and loss of expression of PTEN was found (Saal, Holm et al. 2005; 
Perez-Tenorio, Alkhori et al. 2007; Stemke-Hale, Gonzalez-Angulo et al. 2008; Li, Zhu et al. 
2010). 
 
 
6.4 Association of PIK3CA mutations with clinicopathological markers 
The association of PIK3CA mutations with clinicopathological parameters is still under debate. 
PIK3CA mutations associate significantly with ER- and PR-positive tumors (Saal, Holm et al. 
2005; Li, Rong et al. 2006; Maruyama, Miyoshi et al. 2007; Kalinsky, Jacks et al. 2009; Li, Zhu et 
al. 2010) although some studies failed to find significant association of PIK3CA mutations and 
ER (Buttitta, Felicioni et al. 2006; Barbareschi, Buttitta et al. 2007; Michelucci, Di Cristofano et 
al. 2009). In some studies an association of mutant PIK3CA with overexpression of the growth 
factor receptor ErbB2 (Saal, Holm et al. 2005) was observed whereas in other studies no such 
correlation could be detected (Li, Rong et al. 2006; Maruyama, Miyoshi et al. 2007; Li, Zhu et al. 
2010) or even an inverse correlation was observed (Buttitta, Felicioni et al. 2006; Perez-Tenorio, 
Alkhori et al. 2007; Kalinsky, Jacks et al. 2009). Further, mutations in PIK3CA correlated with the 
occurrence of lymph node metastases (Saal, Holm et al. 2005) whereas other studies failed to 
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detect a positive association with lymph node metastases (Buttitta, Felicioni et al. 2006; 
Maruyama, Miyoshi et al. 2007) or found H1047R mutations to anti-correlate with lymph node 
involvement (Kalinsky, Jacks et al. 2009). No association of mutant PIK3CA with mutation in the 
tumor suppressor gene TP53 was observed (Buttitta, Felicioni et al. 2006; Li, Rong et al. 2006; 
Maruyama, Miyoshi et al. 2007). Furthermore, no association with several clinicopathological 
markers was apparent when the helical and kinase domain mutation were analysed separately 
(Barbareschi, Buttitta et al. 2007). 
In one report, the presence of PIK3CA mutations correlated with tumor diameter and 
with well differentiated histology (Li, Rong et al. 2006), while in other reports no association of 
PIK3CA mutations with tumor size and histological grade was observed (Buttitta, Felicioni et al. 
2006; Maruyama, Miyoshi et al. 2007). In one study, even an association of PIK3CA mutations 
with small tumor size was reported (Perez-Tenorio, Alkhori et al. 2007). 
In terms of tumor histology, PIK3CA mutations were observed more frequently in 
invasive lobular carcinomas (ILC) (45% with PIK3CA mutations) than in invasive ductal 
carcinomas (IDC) (25%) (Buttitta, Felicioni et al. 2006; Maruyama, Miyoshi et al. 2007). 
Interestingly, a particular correlation of helical domain mutations with lobular carcinomas could 
be detected while no difference in the distribution of kinase domain mutations was found 
(Buttitta, Felicioni et al. 2006; Barbareschi, Buttitta et al. 2007). 
Similar frequencies of PIK3CA sequence alterations were observed in carcinomas in situ 
and adjacent invasive carcinomas suggesting that genetic mutations in PIK3CA occur relatively 
early in breast tumorigenesis (Dunlap, Le et al. 2010; Li, Zhu et al. 2010; Miron, Varadi et al. 
2010). This finding is consistent with a report that PIK3CA mutations were observed in breast 
tumor samples from various stages (I-IV) (Saal, Holm et al. 2005). Since PIK3CA mutations were 
rarely detected in ductal intraepithelial neoplasias (IDN) PIK3CA events mostly seem to occur 
during progression from IDN to the carcinomas in situ (Li, Zhu et al. 2010). 
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6.5 PIK3CA mutations and patient outcome 
Studies of PIK3CA mutants with respect to metastases-free survival and overall patient survival 
are contradictory. While some studies did not find a correlation of PIK3CA mutations with 
patient prognosis (Saal, Holm et al. 2005; Stemke-Hale, Gonzalez-Angulo et al. 2008; 
Michelucci, Di Cristofano et al. 2009) other studies associated PIK3CA mutations with worse 
outcome (Li, Rong et al. 2006) while in yet other reports a favorable outcome was associated 
with PIK3CA mutations (Maruyama, Miyoshi et al. 2007; Kalinsky, Jacks et al. 2009). The 
association of PIK3CA mutations with favorable patient outcome appears to be paradoxical 
given the potent transformation potential of PIK3CA mutation in vitro (Meyer and Bentires-Alj 
2010). One possible explanation for this “PIK3CA paradox” is that most experimental models 
assess effects on primary tumor growth and not metastases and long-term survival. 
Alternatively, PIK3CA mutations might only moderately activate the pathway and/or 
constitutive activity of mutant PIK3CA may induce negative feedback loops that preclude a 
more pronounced activation of the pathway (Li, DeFea et al. 1999). 
Interestingly, there was a significant difference between E542K/E545K and H1047R 
mutations in terms of patient outcome. While H1047R mutations were associated with 
improved survival (Barbareschi, Buttitta et al. 2007; Kalinsky, Jacks et al. 2009), E542K/E545K 
mutations predict poor prognosis for disease-free survival (Barbareschi, Buttitta et al. 2007). Of 
note, in the latter study no association with survival was found when both classes of PIK3CA 
mutation were combined (Barbareschi, Buttitta et al. 2007). Another group associated 
particularly H1047R mutations with a worse patient outcome, however, in these studies either 
only IDCs were used excluding for example ILCs in which helical domain mutations were shown 
to be enriched (Lai, Mau et al. 2008) or only aggressive ErbB2-positive and triple negative 
cancers, in which PIK3CA mutation are very rare, were analyzed (Lerma, Catasus et al. 2008; 
Michelucci, Di Cristofano et al. 2009). 
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Rationale and Aims of the Work 
Breast cancer is the most common form of cancer in women and accounts for more than 
450’000 deaths worldwide annually. Breast cancer treatment includes surgery, radio-, and 
chemotherapy, as well as targeted therapy for ER-positive and ErbB2-positive tumors. Many 
breast cancer patients show either de novo or acquired resistance to those therapies 
highlighting the urgent need for new therapeutic targets and preclinical models in which the 
molecular mechanisms of treatments and resistance can be studied. 
PIK3CA, which encodes the alpha catalytic subunit of PI3K, was found to be mutated at a 
high frequency in various types of cancer including breast cancer. These mutations result in 
constitutive activation of the enzyme and were demonstrated to be transforming in vitro and in 
vivo, however, whether mutant PIK3CA can initiate mammary carcinomas in mice was 
unknown.  
Mouse models of breast cancer including various transgenic mice overexpressing 
activated ErbB2 have made significant contributions to the understanding of the biology of 
breast cancer.  Given the high frequency of PIK3CA mutations in breast cancer, we decided to 
generate and characterize mouse models expressing the two most common activating 
mutations (E545K and H1047R). Our aims were: 
1) to investigate whether PIK3CA mutations induce carcinomas in the mouse and to 
characterize such tumors both, histologically and molecularly 
2) to identify molecular differences between E545K- and H1047R-evoked tumors 
3) to identify the cell(s)-of-origin for mutant PIK3CA-driven mammary tumors 
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Results and discussion of the published manuscript “Luminal 
Expression of PIK3CA Mutant H1047R in the Mammary Gland 
Induces Heterogeneous Tumors” 
Expression of PIK3CA H1047R in luminal mammary epithelial cells induces 
carcinomas 
To test whether PIK3CA H1047R evokes mammary carcinoma, we generated transgenic mice 
that conditionally expressed this mutation in the mammary epithelium. The correct integration 
of the construct in ES cells conditionally expressing PIK3CA H1047R (Figure 1A) was tested by 
Southern blotting and PCR (Figure 1B and data not shown). The ES cells were used to generate 
the H1047R line and the mutation was confirmed by DNA sequencing (Figure 1B right). Next, 
H1047R animals were crossed to WAPiCre mice in which expression of recombinase Cre was 
driven by the whey acidic protein (WAP) promoter that is active in alveolar progenitor cells and 
differentiated secretory luminal cells (Wintermantel, Mayer et al. 2002; Boulanger, Wagner et 
al. 2005; Booth, Boulanger et al. 2007; Bruno and Smith 2010). We also crossed H1047R animals 
to mice expressing Cre under the control of the mouse mammary tumor virus long terminal 
repeat (MMTV-Cre), which results in expression within luminal mammary epithelial cells 
(Andrechek, White et al. 2005). 
Female bi-transgenic WAPiCre H1047R mice and littermate controls (WAPiCre) were 
generated. Mammary glands from WAPiCre H1047R virgin mice had GFP-positive areas 
indicating expression of the oncogene (Figure 1C left). This is consistent with previous studies 
that reported activity of the WAP promoter in a fraction of mammary epithelial cells in virgin 
mice (Booth, Boulanger et al. 2007; Bruno and Smith 2010). Examination of whole-mounts and 
hematoxylin and eosin (H&E)-stained sections revealed on average 5.7 (±2.2) neoplastic lesions 
in glands from 21- to 24–week-old virgin WAPiCre H1047R mice but not from up to 18–week-
old WAPiCre H1047R virgin or age matched littermate controls (Figure 1C right). 
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Figure 1. Targeted expression of mutant p110α in luminal mammary epithelial cells. (A) Schematic of the 
construct used for generating transgenic mice conditionally expressing PIK3CA H1047R. The PIK3CA cDNA is 
flanked by a floxed STOP cassette upstream and an IRES2-EGFP reporter element downstream. Expression of 
PIK3CA H1047R is driven by a chicken β-actin (CAGS) promoter. (B) Southern blotting of genomic DNA from wild-
type and PIK3CA H1047R mice (left) and sequencing of genomic DNA from H1047R transgenic mice harboring a A 
to G mutation at nucleotide 3140 (right). (C) Left panel: Fluorescence images of glands from virgin WAPiCre control 
and virgin WAPiCre H1047R mice showing GFP expression. Right panel: Representative images of mammary glands 
from WAPiCre control mice (left), WAPiCre H1047R virgin mice between 12 and 18 weeks old (center), and 
WAPiCre H1047R virgin mice between 21 and 24 weeks old (right). Images show whole-mount preparations (top) 
and H&E-stained sections (bottom). The red arrows indicate neoplastic lesions. Inserts show the indicated areas at 
higher magnification. Table shows quantification of neoplastic lesions. Scale bars = 1 mm (whole mounts, 
fluorescence images) and 100 μm (H&E images). 
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The WAPiCre H1047R and control mice were impregnated to achieve maximal Cre-
mediated recombination and the pubs were removed the day after delivery. Whereas parous 
WAPiCre mice did not form tumors, WAPiCre H1047R mice developed mammary tumors on 
average 36.8 (±4.9) days after delivery of the pups, corresponding to an age of 140.3 (± 6.9) 
days (Figure 2A). Bi-transgenic MMTV-Cre H1047R mice and littermate controls (MMTV-Cre) 
were generated and left as virgins. Surprisingly, ~75% of the MMTV-Cre H1047R animals died 
before the age of 4 months. Although we did not identify the cause of death, we consider that 
leakiness of the MMTV promoter causing deleterious H1047R expression in tissues other than 
the mammary gland was a likely cause (D.S.M. and M.B-A., unpublished observations). 
However, ~25% of the MMTV-Cre H1047R mice were viable and formed mammary carcinomas 
on average after 214 (±22.6) days, whereas no tumors were detected in MMTV-Cre control 
mice (Figure 2B). 
Since the average age of tumor onset between parous WAPiCre H1047R and virgin 
MMTV-Cre H1047R mice differs by ~75 days (140.3 vs. 214 days), we sought to investigate 
whether pregnancy accelerates PIK3CA H1047R-driven tumorigenesis. To address this question 
we compared tumor onset in nulliparous and parous WAPiCre H1047R mice and found tumor 
onset to occur significantly earlier in parous mice than in nulliparous mice (Figure 2C). These 
data show that pregnancy accelerates tumor onset in WAPiCre H1047R mice. 
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Figure 2. WAPiCre H1047R and MMTV-Cre H1047R mice develop mammary tumors. (A) Kaplan-Meier curves 
showing tumor onset in bi-transgenic WAPiCre H1047R mice (n=12) and WAPiCre littermate controls (n=7). The 
mice were impregnated and the pups removed from the mothers the day after delivery. Bi-transgenic animals 
developed palpable tumors on average 36.8 (±4.9) days after delivery, corresponding to age 140.3 (±6.9) days. (B) 
Kaplan-Meier curves showing tumor onset in double transgenic MMTV-Cre H1047R mice (n=7) and MMTV-Cre 
littermate controls (n=8). MMTV-Cre H1047R mice developed palpable tumors on average within 214 (±22.6) days. 
(C) Kaplan-Meier curves showing tumor onset in virgin WAPiCre H1047R (n=7) and parous WAPiCre H1047R mice 
(n=12). Parous animals developed palpable tumors on average at 140.3 (±6.9) days and all animals had at least one 
tumor within 183 days of age. In contrast, by 170 days, only one out of seven virgin WAPiCre H1047R mice 
developed a tumor (at 141 days). The difference in tumor latency between parous and virgin animals is significant 
(P = 0.0006). 
 
We then assessed the mechanisms underlying the accelerated tumor onset seen in 
parous vs. nulliparous WAPiCre H1047R mice. Fluorescence images and Western Blot analysis 
showed enhanced GFP expression in glands from parous mice indicating an increase in the 
number of cells that underwent Cre-mediated recombination and thus expressed H1047R 
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(Figure 3). In addition, whole mounts of the involuting glands revealed a dramatic delay in 
involution in mice expressing PIK3CA H1047R compared with control animals (Figure 4A), which 
is in line with previous reports of a delayed involution when the PI3K pathway is hyperactivated 
(Schwertfeger, Richert et al. 2001; Li, Robinson et al. 2002). Immunostaining for cleaved 
caspase-3 revealed a decrease in the number of apoptotic cells in involuting glands from 
WAPiCre H1047R mice compared with control mice, suggesting that reduced cell death is the 
cause of the delayed involution (Figure 4B,C). Our results suggest, therefore, that the 
acceleration of tumor onset is most likely due to an increase in the number of cells expressing 
PIK3CA H1047R in parous glands and to impaired cell death in involuting glands with the 
H1047R mutation. Indeed, pregnancy-induced proliferation could facilitate the acquirement of 
further genomic alterations and therefore accelerates tumorigenesis. 
      
 
Figure 3. GFP expression in glands from virgin and parous WAPiCre H1047R mice. Fluorescence images of a gland 
from WAPiCre H1047R virgin mouse (left) and of a day 8-involuting gland (right) showing GFP expression (upper 
panel). Immunoblotting of mammary gland lysates from virgin and parous WAPiCre H1047R mice as indicated 
(lower panel). Scale bars = 1 mm. 
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Figure 4. Expression of PIK3CA H1047R delays mammary gland involution. (A) Representative images of 
involuting glands. The pups were removed from the mothers the day after delivery and the glands isolated 2 days 
(left panel) and 8 days (right panel) later. Whole mounts (left) and H&E-stained sections (right) are shown. (B) 
Cleaved caspase-3 immunostainings for glands at involution day 2 for both the WAPiCre control (left) and WAPiCre 
H1047R mice (right). (C) Relative proportion of cleaved caspase-3-positive cells in day 2-involuting glands from 
WAPiCre control (left) and WAPiCre H1047R mice (right). * P < 0.001. Scale bars = 1 mm (whole mounts) and 100 
μm (H&E images). 
 
Part I: PIK3CA H1047R Induces Heterogeneous Mammary Carcinomas 
 
 
37 
 
Analysis of RNA and proteins from WAPiCre H1047R and MMTV-Cre H1047R-induced 
tumors confirmed that mutant PIK3CA was expressed in the bi-transgenic mice (Figure 5A, B). In 
addition, tumors from both WAPiCre H1047R and MMTV-Cre H1047R mice showed threefold 
higher phospho-Akt levels than mammary tumors from the MMTV-NeuNT model. In contrast, 
activation of the Erk1/2 pathway in PIK3CA H1047R tumors tended to be weaker than in tumors 
from MMTV-NeuNT mice (Figure 5C). 
Our results show that luminal expression of PIK3CA H1047R induces mammary tumor 
formation. This is consistent with the observation that conditional expression of mutant PIK3CA 
H1047R in type II lung alveolar epithelial cells causes lung adenocarcinomas in transgenic mice 
(Engelman, Chen et al. 2008) and suggests that this mutation plays a causal role in epithelial 
cancers. 
 
 
Part I: PIK3CA H1047R Induces Heterogeneous Mammary Carcinomas 
 
 
38 
 
 
Figure 5. Tumors from WAPiCre H1047R and MMTV-Cre H1047R mice express mutant PIK3CA. (A) RT-PCR 
showing expression of PIK3CA H1047R in WAPiCre H1047R and MMTV-Cre H1047R mammary tumors but not in 
heart or kidney of a WAPiCre H1047R animal. (B) Expression of exogenous p110α as indicated by P110α-
immunoprecipitation (IP) from MMTV-NeuNT, WAPiCre H1047R, and MMTV-Cre H1047R tumor lysates using anti-
p110α (left) or anti-HA antibodies (right). (C) Immunoblotting of mammary tumor lysates from the indicated 
genotypes using the specified antibodies (left) and quantification of pErk1/2 and pAkt S473 signals (right). * not 
significant; **P <0.01; SN: supernatant. 
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WAPiCre H1047R and MMTV-Cre H1047R-evoked mammary tumors are 
heterogeneous 
To gain insight into significant patho-physiological features, 22 WAPiCre H1047R and 21 MMTV-
Cre H1047R-induced mammary tumors were characterized histologically. MMTV-Cre H1047R-
caused tumors showed multiple adenomyoepitheliomas, with clusters of well-delineated 
polypoid tumors composed of a mixture of glandular epithelium and interstitial fusiform cells 
with abundant polar cytoplasm (Figure 6 top row left). Similar tumors have been reported in 
MMTV-Cre/Ptenfl/fl/ErbB2KI mice, suggesting that an activated PI3K pathway mediates this 
histotype (Schade, Rao et al. 2009). 
In contrast, the WAPiCre H1047R mice formed a more diverse spectrum of tumors with 
five distinct histotypes. The most prevalent tumor phenotypes found are adenosquamous 
carcinomas (54.6%) and adenomyoepitheliomas (22.7%). Adenocarcinomas with squamous 
metaplasia (13.6%) and adenocarcinomas (9.1%) were also observed albeit at lower frequencies 
(Figure 6 top row and Figure 7A). All the glands surrounding the tumors displayed diffuse 
adenocarcinomatosis with invasive periductal cords of neoplastic epithelial cells in dense 
connective tissue (Figure 6 top row right). 
To further characterize H1047R-induced carcinomas, tumors were stained for luminal 
cytokeratin 18 (K18), basal/myoepithelial cytokeratin 14 (K14), and myoepithelial α-smooth 
muscle actin (α-SMA) markers, as well as for ER and the progesterone receptor (PR). Notably, 
~18 to ~26% of the tumor cells of the adenomyopitheliomas from both transgenic mice 
expressed ER and ~16% expressed PR in the luminal cells (Figure 6 and Figure 7B). Other tumor 
histotypes also contained ER-positive cells but at lower frequencies (<5%) (Figure 6 and Figure 
7B). WAPiCre- and MMTV-Cre H1047R tumors were positive for both luminal K18 and basal 
K14. The relative tumor area positive for K14 was ~15% in adenomyoepitheliomas and 
adenocarcinomatosis, whereas in the other phenotypes it ranged between 26% and 43%. The 
percentage of K18-positive tumor area was 25% in adenocarcinomatosis and ranged between 
36 to 45% in the other tumor histotypes (Figure 6 and Figure 7B). Although the majority of 
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tumor cells expressed either K18 or K14, some cells were positive for both K14 and K18 (Figure 
8A). As expected, the K14-positive cells within WAPiCre- and MMTV-Cre H1047R 
adenomyoepitheliomas were also α-SMA-positive (Figure 6). In contrast, the K14-positive cells 
within adenosquamous carcinomas observed in WAPiCre H1047R mice were largely negative 
for α-SMA, a characteristic of human metaplastic breast cancer in which PIK3CA is mutated in 
~50% of cases (Hennessy, Gonzalez-Angulo et al. 2009). Interestingly, all tumors showed very 
low rates of apoptosis (0.2-1.4%) (Figure 6 and Figure 7B), most likely due to the anti-apoptotic 
effect of an activated PI3K pathway. We also found the percentage of Ki-67-positive cells to be 
lower in adenomyoepitheliomas and adenocarcinomatosis than in all other tumor phenotypes 
(Figure 6 and Figure 7B). 
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Figure 6. WAPiCre H1047R and MMTV-Cre H1047R-evoked tumors express basal markers. (A) H&E-stained 
sections and immunostainings for ER, K18, K14, and α-SMA from MMTV-Cre H1047R adenomyoepithelioma and 
different WAPiCre H1047R tumor histotypes as indicated. 
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Figure 7. Quantification of H1047R-evoked tumors. (A) Relative prevalence of adenosquamous carcinoma (blue), 
adenomyoepithelioma (red), adenocarcinoma with squamous metaplasia (green), and adenocarcinoma (purple) 
among MMTV-Cre H1047R and WAPiCre H1047R-evoked tumors. (B) The table summarizes histological analysis for 
the markers ER, PR, K18, K14, α-SMA, Ki-67, and cleaved caspase-3 in 25 different tumors consisting of five distinct 
tumor histotypes from both WAPiCre H1047R and MMTV-Cre H1047R mice. Indicated is the proportion of positive 
tumor cells (ER, PR, Ki-67, cleaved caspase-3) or the positive tumor area (K18, K14, α-SMA). 
 
 
Figure 8. (C) Fluorescent image of DAPI staining (blue) and immunostaining of K18 (green) and K14 (red) in a 
WAPiCre H1047R tumor section. The arrow indicates K14/K18 double-positive cells. Asterisks indicate K14 and K18 
single-positive cells. (D) Images of immunostaining for GFP and K14 in WAPiCre H1047R (top) and MMTV-Cre 
H1047R tumor sections (bottom). Arrows indicate areas of K14/GFP double-positive cells. Scale bars = 100 μm. 
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These data show that luminal expression of PIK3CA H1047R can induce mammary 
tumors expressing the basal marker K14. To exclude the possibility that luminal PIK3CA H1047R 
induces expression of paracrine factors that transform basal cells, we analyzed K14-positive 
cancer cells for GFP expression by immunostaining and FACS. There was a significant overlap 
between K14 and GFP expression (Figure 8B), suggesting that some K14-positive cancer cells 
within the WAPiCre H1047R and MMTV-Cre H1047R tumors resulted from expression of the 
oncogene in luminal cells. This supports the emerging notion that some tumors with basal 
characteristics arise from luminal cells (Lim, Vaillant et al. 2009; Molyneux, Geyer et al. 2010). 
Taken together, our results show that luminal expression of PIK3CA H1047R evokes 
mammary tumors, recapitulating the heterogeneity of human breast cancer. These results lead 
to major conclusions. The finding that PIK3CA H1047R causes ER- and PR-positive tumors 
suggests that PI3K activity expands ER-positive mammary cells, consistent with the presence of 
PIK3CA H1047R mutations in human ER-positive tumors (Saal, Holm et al. 2005). 
The presence of cancer cells expressing luminal and basal markers in WAPiCre- and 
MMTV-Cre H1047R-evoked tumors suggests in both models that multipotent progenitor cells 
are the targets of H1047R-mediated transformation. The WAP promoter is active in a 
multipotent progenitor population, the parity-identified mammary epithelial cells (PI-MECs), 
which are present in nulliparous mice and are expanded after pregnancy (Booth, Boulanger et 
al. 2007; Bruno and Smith 2010). Tumors that developed in WAPiCre H1047R nulliparous mice 
most likely derived from PI-MECs because this is the cell population that expresses WAP-driven 
Cre in glands from nulliparous mice (Bruno and Smith 2010). PI-MECs were shown recently to 
be the target of MMTV-NeuNT-driven carcinogenesis (Bruno and Smith 2010; Jeselsohn, Brown 
et al. 2010). Therefore, it is plausible that PI-MECs are the cells-of-origin of cancer in both 
WAPiCre- and MMTV-Cre H1047R-evoked tumors but at this stage we cannot completely 
exclude that expression of PIK3CA H1047R in more differentiated cells also contributes to 
tumor formation in these models. 
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Figure 9. H&E-stained sections and immunostainings for K18 and K14 from MMTV-NeuNT-evoked tumors. Scale 
bars = 100 μm. 
 
The observation of different histotypes between WAPiCre H1047R- and MMTV-Cre 
H1047R-derived tumors has several possible explanations. First, WAPiCre H1047R mice but not 
MMTV-Cre H1047R mice went through pregnancy. Second, it is possible that the cellular targets 
of MMTV- and WAP- are overlapping but not congruent.  
The fact that tumors from MMTV-Cre H1047R but not MMTV-NeuNT mice express K14 
(Figure 6 and Figure 9) suggests a model in which PIK3CA H1047R transforms multipotent 
progenitors, allowing differentiation along the luminal and basal lineages. In contrast, the 
NeuNT oncogene favors luminal differentiation resulting in K18-positive but not K14-positive 
tumors. An alternative and more interesting explanation is that the MMTV promoter is active in 
differentiated luminal cells and H1047R causes their dedifferentiation to multipotent 
progenitor cells, which then give rise to K14- and/or K18-positive cancer cells. This would 
suggest a role for PIK3CA H1047R in cancer cell plasticity, a hypothesis that merits testing. 
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Results 
WAPiCre E545K but not PIK3CA wild-type mice form mammary tumors 
In order to test whether expression of wild-type PIK3CA (PIK3CAwt) or the helical domain 
mutation E545K induces mammary tumors we generated transgenic mice that carry a 
conditional allele of human PIK3CAwt or the E545K mutant cDNA analogous to the H1047R mice 
described before (see Figure 1 in section “Part I: Characterization of the WAPiCre H1047R 
Mouse Model”). We then crossed these mice to WAPiCre mice to obtain mammary gland 
specific expression of the transgenes. The resulting WAPiCre PIK3CAwt and WAPiCre E545K 
females were impregnated to induce maximal WAP activity and Cre-mediated excision of the 
STOP cassette and subsequently monitored for tumor formation. While WAPiCre PIK3CAwt mice 
did not develop mammary carcinomas after 230 days, WAPiCre E545K females had palpable 
tumors after an average of 80.8 (± 8.0) days (Figure 1). 
 
 
Figure 1. WAPiCre E545K mice develop mammary tumors with longer latency than WAPiCre H1047R mice. (A) 
Kaplan-Meier curves showing tumor onset in bi-transgenic WAPiCre H1047R mice (n=12), WAPiCre E545K mice 
(n=10) and WAPiCre PIK3CAwt females (n=7). The mice were impregnated and the pups removed from the mothers 
the day after delivery. Bi-transgenic H1047R animals developed palpable tumors on average 36.8 (±4.9) days after 
delivery, WAPiCre E545K mice formed tumors on average 80.8 (±8.0) days after delivery, whereas WAPiCre 
PIK3CAwt mice did not form palpable tumors after 230 days. 
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PIK3CA E545K is a weaker inducer of mammary carcinomas than H1047R 
Expression of both the helical domain and the kinase domain mutation caused tumor formation 
in vivo, however, the average latency to tumor onset was different (80 days for WAPiCre E545K 
vs. 37 days for WAPiCre H1047R). To gain insight into possible differences in molecular signaling 
pathways activated by the two different p110α mutants we performed immunoblotting for 
various signaling molecules including downstream effectors of PI3K such as Akt and mTOR 
(Figure 2). Surprisingly, lysates from WAPiCre E545K evoked tumors contained comparable 
phospho-levels for Akt, Erk1/2, mTOR and the ribosomal protein S6 which is a downstream 
target of mTOR. This finding suggests that in tumors, both activating mutations of PIK3CA 
activate the investigated downstream signaling to a similar extent. 
 
Figure 2. Tumors from WAPiCre H1047R and WAPiCre E545K mice express comparable levels of p-Akt, p-Erk1/2, 
p-mTOR, and p-S6. Immunoblotting of mammary tumor lysates from the indicated genotypes using the specified 
antibodies. 
 
Discussion and Outlook 
Parous WAPiCre PIK3CAwt mice do not form tumors after 230 days while mice expressing either 
E545K or H1047R mutant p110α develop mammary carcinomas after an average of 80.8 and 
36.8 days after delivery, respectively. This suggests that the tumorigenic effect caused by 
mutant PIK3CA is mostly due to the mutation rather than overexpression of the gene (Figure 1). 
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Furthermore, the shorter tumor latency observed in WAPiCre H1047R mice as compared to 
WAPiCre E545K animals suggests that p110α H1047R is a more potent oncogene than the 
helical domain mutation E545K which is in concordance with a previous study performed on 
chicken embryonic fibroblasts (Bader, Kang et al. 2006). The lipid product PIP3 was 
demonstrated to be essential for p110α-mediated transformation and therefore a simple 
explanation for the difference in tumor latency would be that p110α E545K produces less PIP3 
than H1047R resulting in less activation of the effector Akt and its downstream targets. 
However, levels of S473 phosphorylated Akt and S6, both indicating active PI3K signaling, are 
comparable in E545K- and H1047R-evoked tumors suggesting that the signaling amplitude 
induced by either mutant p110α E545K or H1047R is similar. Based on this finding and the fact 
that the helical and kinase domain mutants have different requirements for Ras and p85 (Zhao 
and Vogt 2008), it is tempting to speculate that these mutations might activate a distinct set of 
downstream pathways. 
In order to test this hypothesis we isolated RNA from a set of WAPiCre E545K and 
H1047R tumors and performed whole genome expression profiles. 
In the future we will: 
1) Test whether WAPiCre E545K mice produce a comparable set of tumor histotypes as 
WAPiCre H1047R mice. For this purpose we harvested tumors from WAPiCre E545K 
mice and we are currently analyzing their histology similar to that of WAPiCre 
H1047R-evoked tumors. 
2) Analyze whole gene expression profiles that we gained from WAPiCre E545K- and 
H1047R-evoked mammary tumors. 
3) Investigate whether involution in WAPiCre E545K mice is delayed as in WAPiCre 
H1047R mice. 
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Results 
Whole body expression of mutant PIK3CA is lethal 
In order to investigate how whole body expression of mutants of p110α affects the physiology 
of mice and whether they induce mammary tumors we crossed mice carrying a conditional 
allele of either wild-type, E545K or H1047R mutant PIK3CA to animals expressing a tamoxifen-
inducible CreERT2 fusion protein under the control of a chicken β-actin promoter (CAGS-
CreERT2 mice). CAGS-CreERT2 mice expressing conditional PIK3CA alleles were treated with 
tamoxifen on five consecutive days before two days without injection followed by another 
tamoxifen treatment for five consecutive days (Figure 1). 
 
 
Figure 1. Tamoxifen induction scheme. Control and CAGS-CreERT2 PIK3CA transgenic mice were injected on 5 
consecutive days with 1 mg tamoxifen. On days 6 and 7, the mice were left untreated before receiving tamoxifen 
injections for an additional 5 consecutive days. Note that in contrast to CAGS-CreERT2 PIK3CAwt or E545K mice, 
CAGS-CreERT2 H1047R mice were never injected with more than 5 doses of tamoxifen because they died within 
the first week of treatment. 
 
To test whether wild-type and mutant PIK3CA is expressed in the bi-transgenic mice and 
in the mammary gland in particular, we isolated mammary epithelial cells from mice of all 
genotypes. After growing them as spheroids in suspension culture for one week to increase the 
number of cells, we isolated RNA and performed reverse transcription-PCR (RT-PCR). Using 
primers specifically binding to the human PIK3CA gene and the HA-tag we detected a PCR 
product in all the transgenic mice but not in the control mice demonstrating expression of the 
transgene (Figure 2). 
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Figure 2. Wild-type and mutant PIK3CA are expressed in CAGS-CreERT2 PIK3CA mice. RT-PCR amplification of 
transgenic HA-PIK3CA was performed on cDNA from mammary cells isolated from mice with the indicated 
genotypes. cDNA from CAGS-CreERT2 mice and water served as negative controls (columns 1 and 6) and plasmid 
containing PIK3CA DNA was used as positive control (column 5). Cells isolated from CAGS-CreERT2 PIK3CAwt, 
E545K, and H1047R mice express the transgene (columns 2-4). RT-PCR amplification of gapdh was performed for 
equal loading (bottom row). 
 
While tamoxifen-induction in CAGS-CreERT2 mice expressing PIK3CA wild-type (CAGS-
CreERT2 PIK3CAwt) caused no obvious phenotype, tamoxifen-treated CAGS-CreERT2 expressing 
mutant PIK3CA E545K or H1047R developed a severe phenotype. CAGS-CreERT2 H1047R 
animals died within one week and CAGS-CreERT2 E545K mice within three weeks. Interestingly, 
even without any tamoxifen administration, both CAGS-CreERT2 H1047R and E545K mice died 
within 2 months and 4 months, respectively, which is most likely due to leakiness of the 
CreERT2 system. Although macroscopic analysis of organs including heart, liver, spleens, and 
colon revealed no obvious phenotype, hematomas on ears, tail and pads were observed (Figure 
3). 
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Figure 3. Whole body expression of mutant PIK3CA is lethal whereas expression of wild-type PIK3CA induces 
mammary carcinomas with a long latency. In the absence of tamoxifen, mice carrying a conditional allele of 
mutant H1047R or E545K develop hematomas on the ears, tail, and pads starting at the age of around 3 weeks. 
Eventually both, CAGS-CreERT2 H1047R and E545K mice, die prematurely within 2 and 4 months, respectively (top 
two panels).  Tamoxifen induction in these mice accelerates the phenotype and leads to death within 1 (CAGS-
CreERT2 H1047R) and 3 weeks (CAGS-CreERT2 E545K). Untreated CAGS-CreERT2 PIK3CAwt mice are of normal 
phenotype and do not die prematurely. Treatment of these mice with tamoxifen does not result in an abnormal 
phenotype at young age, however, at an average age of 429 (±25) days CAGS-CreERT2 PIK3CAwt mice develop 
mammary carcinomas with 100% penetrance as shown by the Kaplan-Meier curves. Red arrows point on 
hematomas observed on untreated CAGS-CreERT2 H1047R and E545K mice (bottom two panels). 
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To check what might cause the rapid death in CAGS-CreERT2 H1047R mice after 
tamoxifen induction, we administrated tamoxifen to CAGS-CreERT2 H1047R and CAGS-CreERT2 
control mice on 3 consecutive days and sent the animals to the company “Frimorfo” (Marly, 
Switzerland) for in-depth analysis. Since the only overt phenotype observed in CAGS-CreERT2 
H1047R mice were hematomas, the analysis carried out by Frimorfo was centered on blood 
coagulation, blood parameters, and metabolic parameters. 
The platelet counts were similar in control and CAGS-CreERT2 H1047R mice and the 
bleeding time and bone marrow histology were normal in the mutant mice. Based on these 
findings, a platelet defect in CAGS-CreERT2 H1047R animals can be excluded. Further, the 
coagulation cascade does not seem to be involved since both, Quick-time and TPP assays, 
produced similar results in control and CAGS-CreERT2 H1047R mice. Histological examination 
did not reveal major abnormalities in the vessel wall, however, in one CAGS-CreERT2 H1047R 
mouse, neovascularization of thrombotic vessels was taking place. In certain mutant animals 
vascular dilation occured, however, the cause for this observation could not be identified. 
Weakness of the vessel wall or a failure of the right heart might be the reason for this 
phenotype. 
Analysis of blood plasma revealed pathological values for some liver and pancreas 
enzymes. The levels of the enzymes glutamic pyruvic transaminase (GPT) and glutamic 
oxaloacetic transaminase were increased ~2 fold and the pancreatic enzyme amylase was 
elevated ~50% in CAGS-CreERT2 H1047R mice compared to control animals. Major differences 
were also detected for plasma metabolites. The plasma levels of glucose in CAGS-CreERT2 
H1047R mice were ~50% and the levels of triglycerides only ~20% of the levels in control 
animals. The detailed Frimorfo report is in the Appendix on page 93. 
Interestingly, induction of CAGS-CreERT2 PIK3CAwt mice with tamoxifen did not cause 
any phenotype comparable to that of PIK3CA mutant mice and the animals were healthy as 
were control mice. However, after a long latency of ~430 days, these mice started to develop 
mammary carcinomas with 100% penetrance. 
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CAGS-CreERT2 H1047R-derived mammary epithelial cells exhibit increased 
sphere-forming capacity 
To investigate whether the MECs from mice expressing wild-type or mutant PIK3CA have 
altered properties regarding self-renewal and proliferation, we isolated cells from the 
mammary glands of transgenic animals and cultured them in suspension as mammospheres. 
Mammospheres were first described by Dontu and co-workers (Dontu, Abdallah et al. 2003) as 
a surrogate assay for stemness/progenitor properties of epithelial cells. A stable number of 
mammospheres simplistically means that every mammosphere contains one mammosphere-
forming cell. If the number of spheres increases with passaging one mammosphere must 
contain more than one sphere-forming cell arguing for enhanced self-renewing to occur. The 
size of the spheres allows conclusions on the proliferative capacity of the sphere-forming 
epithelial cells. 
5’000 freshly isolated mammary cells were seeded as single cells and cultured for one 
week. Interestingly, cells isolated from mammary glands of CAGS-CreERT2 E545K or H1047R 
formed significantly more mammospheres than CAGS-CreERT2 control mice or mice expressing 
wild type PIK3CA (Figure 4A). Moreover, spheres expressing mutant p110α formed larger 
mammospheres (Figure 4B). For the subsequent passage (M1), mammospheres were 
enzymatically digested and 5’000 cells were seeded again as single cells. For the M1 passage 
only CAGS-CreERT2 control- and CAGS-CreERT2 H1047R-derived MECs were seeded. The 
number of mammospheres formed was similar to that in passage M0 (Figure 4A). 
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Figure 4. Mammary cells expressing PIK3CA mutants have enhanced sphere-forming capacity. (A) 5000 freshly 
isolated mammary cells from mice of the indicated genotypes were seeded in triplicates on a 24-well ultra-low 
attachment dish. Cells were grown in suspension for 7 days and the number of mammospheres (>50μm diameter) 
formed in each well was counted. For CAGS-CreERT2 control 15.7 (±3.7), for CAGS-CreERT2 PIK3CA 16.7 (±2.0), for 
CAGS-CreERT2 E545K 31.0 (±4.5), and for CAGS-CreERT2 H1047R 46.7 (±3.2) mammospheres were formed on 
average (M0, top). Mammospheres were enzymatically digested into single cells which were seeded again (M1, 
bottom). (B) Examples of typical M0 mammospheres from CAGS-CreERT2 control (top) and CAGS-CreERT2 H1047R 
cells are shown (bottom). Scale bar represents 200 μm. 
 
Expression of H1047R results in an accumulation of a mammary epithelial cell 
population enriched in ER-negative cells 
We next assessed whether expression of H1047R altered the mammary epithelial cell hierarchy. 
We isolated MECs from untreated seven-week old CAGS-CreERT2 control and H1047R mice and 
excluded lymphocytes via CD45 negative selection. Using the cell surface markers Sca-1 and 
CD24, we separated the epithelial cells into three subpopulations: Sca-1neg CD24med (enriched in 
stem cells and myoepithelial cells), Sca-1neg CD24high (enriched in ER- luminal epithelial cells), 
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and Sca-1pos CD24high (enriched in ER+ luminal epithelial cells). Analysis of MECs from glands 
expressing H1047R revealed a much less clear resolution into the subpopulations showing only 
two major populations (Figure 5A). Since the mice used for the FACS analysis were not induced 
with tamoxifen, only 25-35% of the epithelial cells were GFP-positive and therefore the density 
plot in Figure 5A represents the overlap of H1047R-expressing and –non-expressing cells. When 
we restricted the analysis on the H1047R cells expressing GFP, resolution into the three 
subpopulations was possible, however, a dramatic accumulation of Sca-1neg CD24high cells was 
manifested (Figure 5B). While in the normal gland ~30% of the epithelial cells are Sca-1neg 
CD24high this population accounts for ~85% of mutant epithelial cells (Figure 5B). These data 
suggest that H1047R expression results in an accumulation of the Sca-1neg CD24high cell 
population. 
 
Figure 5. FACS analysis of cells from CAGS-CreERT2 H1047R mammary glands reveals a dramatic accumulation of 
Sca-1neg CD24high cells. (A, top) Mammary gland cells were isolated from at least 7 mice and digested to single cells 
which were stained for CD45, CD24 and Sca-1. The CD45- epithelial cells from both control (left) and CAGS-CreERT2 
H1047R mutant mice (right), were separated based on their expression levels of CD24 (x-axis) and Sca-1 (y-axis). 
(A, bottom). Histograms show expression levels of GFP (x-axis) in mammary epithelial cells from above. (B) 
Distribution of only GFP+ mammary epithelial cells from CAGS-CreERT2 H1047R mice based on their expression 
levels of CD24 (x-axis) and Sca-1 (y-axis). 
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CAGS-CreERT2 H1047R mutant MECs produce aberrant outgrowths and 
mammary tumors eventually 
The major aim of generating mice expressing mutant PIK3CA H1047R in all cells (CAGS-CreERT2 
H1047R) was to investigate whether such mice would develop mammary carcinomas and, if so, 
whether these tumors are different from tumors formed in mice specifically expressing mutant 
H1047R in luminal mammary epithelial cells (WAPiCre H1047R). Since CAGS-CreERT2 H1047R 
mice die before overt tumor onset, we transplanted the mammary epithelium of CAGS-CreERT2 
H1047R and CAGS-CreERT2 control mice into wild-type Balb/c recipient mice. We isolated the 
mammary glands of the donor mice, chopped them into pieces, and digested them 
enzymatically. The resulting organoids were incubated as suspension culture over night and 
injected the next day into cleared fat pads of three-week old recipient mice. The outgrowth was 
scored six to twelve weeks after the transplantation. Whole mount preparations revealed that 
transplanted control epithelium repopulated the whole fat pad while H1047R mutant 
epithelium was hyperplastic and repopulated the fat pad only partially (Figure 6A). H&E 
stainings prepared from glands isolated six weeks after transplantation confirmed the 
hyperplastic phenotype of H1047R mutant epithelium (Figure 6B). 
 
Figure 6. CAGS-CreERT2 H1047R derived mammary epithelial cells form aberrant outgrowths in vivo. (A) 
Mammary glands from donor CAGS-CreERT2 control and CAGS-CreERT2 H1047R mice were isolated and digested 
enzymatically. The resulting organoid suspension was injected with matrigel into cleared fat pads of three-week 
old Balb/c recipients. 6 weeks after transplantation the glands were harvested and prepared as whole mounts. 
Scale bars represent 2mm. (B) H&E sections showing outgrowth produced by CAGS-CreERT2 H1047R (left) and 
control epithelium (right). Scale bar represents 100 μm. 
Part III: Total Body Expression of Mutant PIK3CA is Lethal and Affects MEC Properties 
 
 
58 
 
 
The recipient mice transplanted with control or mutant epithelium were monitored for 
tumor formation. As expected, mice transplanted with control tissue did not form any tumors 
while mice with H1047R mutant epithelium developed mammary carcinomas after 221.3 
(±20.3) days. By the end of the study 16 mice that formed H1047R mutant donor epithelium 
outgrowths developed a mammary tumor while only 3 mice did not (Figure 7). 
 
Figure 7. CAGS-CreERT2 H1047R-derived mammary epithelial cells form tumors in vivo. Kaplan-Meier curves 
showing tumor onset in Balb/c mice transplanted with CAGS-CreERT2 H1047R mutant epithelium (n=19). 16 mice 
developed palpable tumors on average 221.3 (±20.3) days after transplantation. Three mice (15.8 %) showed 
aberrant outgrowths but did not form a mammary tumor by the end of the study (320 days after transplantation). 
 
Discussion and Outlook 
Upon tamoxifen induction the three CAGS-CreERT2 PIK3CA transgenic mouse lines express 
either wild-type or mutant PIK3CA E545K or H1047R. Expression of H1047R or E545K caused 
premature death within one or three weeks, respectively. Since there is a certain degree of 
leakiness inherent to this Cre-mediated recombination system (data not shown), even CAGS-
CreERT2 H1047R and E545K mice that were not induced with tamoxifen died within two or four 
months, respectively. We found that, starting from the age of three weeks, transgenic mice 
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started to develop large hematomas underneath the skin of the ears, tail, and pads (Figure 3) 
without the administration of tamoxifen. This suggested a coagulation problem or enhanced 
leakiness of blood vessels as a result of mutant p110α expression. Further analysis of the 
transgenic animals by Frimorfo (Marly, Switzerland), however, revealed that a platelet defect 
can be excluded and that bleeding time and blood coagulation are not affected in CAGS-
CreERT2 H1047R mice. 
Of note, CAGS-targeted expression of the transgene seems to affect various organs 
including liver, pancreas, and the cardiovascular system (blood vessels) as plasma levels of 
some liver and pancreatic enzymes and of the metabolites glucose and triglycerides are 
pathologic. The dramatic change in glucose and triglycerides might not be surprising given the 
important role of PI3K and its downstream effectors in the regulation of metabolism 
(Engelman, Luo et al. 2006; Manning and Cantley 2007). Recently, p110α was demonstrated to 
be an important mediator of insulin metabolic action in liver and glucose homeostasis and 
ablation of p110α in the liver caused an increase of serum glucose levels which is in line with 
our finding of decreased glucose levels in the PIK3CA H1047R mutant mice (Sopasakis, Liu et al. 
2010). 
In conclusion, the examination by Frimorfo shows that bleeding time and blood 
coagulation are not affected in CAGS-CreERT2 H1047R mice. Although PIK3CA H1047R 
expression affects plasma levels of glucose and triglycerides and causes pathological levels of 
some liver and pancreatic enzymes the cause for the hematomas and premature death remains 
unclear and merits further analysis. Of note, CAGS-CreERT2 E545K show hematomas much like 
CAGS-CreERT2 H1047R mice and die prematurely albeit with a longer latency. The fact that 
CAGS-CreERT2 E545K mice show a similar but weaker phenotype than CAGS-CreERT2 H1047R 
mice is interesting and is in line with the weaker potency of E545K to induce mammary 
carcinomas in mice as compared to H1047R mice. Once more, this raises the question about the 
mechanism explaining this difference in potency. The easiest explanation would be that E545K 
is a less potent activator of downstream signaling than H1047R. However, at least in mammary 
carcinomas, induced by mutant p110α, no difference in the signaling amplitude could be 
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detected using phosphorylation of Akt, mTOR, and S6 as read-outs. As discussed in the previous 
section, it might be that the two types of mutations activate a slightly different set of 
downstream pathways, a hypothesis that merits testing. 
The observation that tamoxifen-induced CAGS-CreERT2 PIK3CAwt mice develop 
mammary tumors after ~430 days is interesting for two reasons. On the one hand, this is the 
only obvious phenotype that we observed with any mouse model expressing wild-type PIK3CA 
(WAPiCre PIK3CAwt, CAGS-CreERT2 PIK3CAwt) and demonstrates that the additional copy of 
human PIK3CA on top of endogenous PIK3CA allows transformation and induction of mammary 
tumors in mice. On the other hand, we have not observed any tumors in mice expressing wild-
type PIK3CA targeted by the WAP promoter 240 days after delivery which corresponds to ~320 
days of age (see Figure 1, part II) indicating that the WAPiCre PIK3CAwt mice might develop 
tumors as well as they become older. Alternatively, and more interestingly, the CAGS promoter 
might target PIK3CAwt expression to a mammary epithelial subpopulation which is susceptible 
to PIK3CAwt-evoked tumorigenesis but not targeted by the WAP promoter. 
When cells from mammary glands of CAGS-CreERT2 PIK3CA mutant mice were seeded 
in suspension they formed more mammospheres which are generally larger than those derived 
from control mice. In line with the difference in tumor latency and induction of premature 
death, this phenotype was more pronounced in cells expressing H1047R which formed around 
three times more mammospheres than control cells whereas cells expressing E545K formed 
only twice the number of spheres than control cells. Interestingly, no difference in sphere 
number was observed in cells expressing wild-type PIK3CA as compared to control cells, 
suggesting that the enhanced sphere-forming capacity of cells expressing mutant PIK3CA is due 
to the oncogenic mutation rather than overexpression. The fact that after one passage the 
number of spheres remained the same in both control and H1047R mutant cells (Figure 4A), 
suggests that expression of mutant PIK3CA does not affect the self-renewing capacity of mutant 
MECs but may still affect survival of these cells. However, more and larger spheres were formed 
by mammary cells expressing mutant PIK3CA indicating that the proliferative capacity of these 
cells is enhanced. In concordance with our findings, Korkaya et al. found that activation of the 
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PI3K pathway via PTEN knockdown in human MECs increased the number and size of 
mammospheres in suspension (Korkaya, Paulson et al. 2009). 
While control organoids reconstituted the whole fat pad, when transplanted into 
cleared recipient glands, CAGS-CreERT2 H1047R-derived organoids produced outgrowths that 
were hyperplastic and the mutant epithelium reconstituted the fat pad only partially (Figure 
6A). We can only speculate why mutant mammary epithelium results in solely partial 
outgrowth in recipient fat pads at this stage of the study. It might be possible that expression of 
mutant PIK3CA results in a depletion of mammary stem cells (Figure 5). Alternatively, there 
might be a defect in cap cells which are required for the protrusion of the mammary epithelial 
cells through the mammary fat pad. The progression of the hyperplasias produced by H1047R 
mutant organoids into carcinomas is in concordance with the oncogenic potential of mutant 
p110α in vivo we and others observed (Figure 2 part I; Figure1 part II) (Adams, Xu et al. ; Bader, 
Kang et al. 2006; Engelman, Chen et al. 2008). It will be interesting to analyze the tumor 
histotypes produced by the transplanted CAGS-CreERT2 H1047R-derived organoids since the 
expression of PIK3CA H1047R is allowed in all the epithelial subpopulations. Therefore other 
cells (e.g. basal epithelial cells) could serve as the cell-of-origin in these glands which might 
result in tumor histotypes different from the ones we observed in tumors where H1047R 
expression was targeted to cells in which the WAP or MMTV promoter is active. 
In FACS experiments, we observed a strong accumulation of cells expressing H1047R 
(GFP-positive cells) within the CD24high Sca-1- population. This population, at least in the normal 
mammary gland, is enriched in ER- luminal epithelial cells and possesses limited mammary 
gland repopulating activity (Sleeman, Kendrick et al. 2007). In contrast, only ~15% of GFP-
positive cells were found in the CD24high Sca-1+ and CD24med Sca-1- population, respectively. 
This data indicates that in CAGS-CreERT2 H1047R transgenic mice the basal cell compartment 
which includes mammary stem cells and myoepithelial cells as well as the ER+ enriched 
population are depleted (Figure 5B). This finding is consistent with reports demonstrating the 
importance of PTEN for the maintenance of hematopoietic stem cells (HSC) as the absence of 
PTEN drove HSCs into cell cycle resulting in the depletion of HSCs and the initiation of leukemia 
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(Yilmaz, Valdez et al. 2006; Zhang, Grindley et al. 2006). In a murine model of prostate cancer, 
deletion of PTEN led to the expansion of a prostatic stem/progenitor cell subpopulation and 
tumor initiation (Wang, Garcia et al. 2006). In light of these observations, we speculate that 
expression of mutant H1047R results in an expansion of a mammary progenitor population that 
eventually gives rise to mammary carcinomas. However, this hypothesis is relying on FACS 
analysis based on the expression of the markers CD24 and Sca-1. Thus, we cannot exclude that 
mammary epithelial cells start to express different levels of CD24 and/or Sca-1 once they 
express H1047R, and therefore, would cause a shift in the FACS profile. Further experiments are 
required to confirm the depletion of basal cells and expansion of a progenitor population 
including transplantation assays and proper characterization and quantification of the FACS 
sorted populations based on the expression of differentiation markers (K14, K18, ER) and 
colony-forming capacity. 
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Summary and Outlook 
 
We demonstrated that expression of PIK3CA E545K or H1047R in the mammary gland evoked 
heterogeneous tumors that recapitulated features of human disease and that a multipotent 
progenitor was likely to be the target of mutant PIK3CA-induced tumorigenesis. Notably, the 
H1047R mutant was a more potent inducer of mammary carcinomas than the E545K mutant.  
We showed that whole body expression of PIK3CA mutants E545K or H1047R in mice 
resulted in premature death, however, the cause of death remains unclear. We further 
demonstrated that H1047R expression in all cells resulted in the formation of mammary 
carcinomas upon transplantation of the mutant mammary epithelium into recipient mice.  Of 
note, expression of H1047R in all cells of the mammary gland resulted in an accumulation of a 
mammary epithelial cell subpopulation that is enriched in ER-negative luminal epithelial cells 
and we therefore speculate that cells within that mammary epithelial subpopulation are the 
targets of H1047R-mediated carcinogenesis. 
In the future the mutant PIK3CA mouse models generated in the present work should 
be helpful for detecting collaborating pathways in mutant PIK3CA-induced tumorigenesis. In 
addition, several kinase inhibitors targeting PI3K are in clinical trials and these mouse models 
should help anticipate potential mechanisms of resistance and test combination therapies that 
may synergize with PI3K inhibition. 
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Material and Methods 
Transgenic Mice 
We constructed a vector with a transcriptional STOP sequence flanked by loxP sites upstream of 
the 5’-terminally HA-tagged human PIK3CA cDNA (Addgene) and an IRES2-EGFP reporter 
element (pIRES2-EGFP vector, Clontech). The resulting loxP-STOP-loxP-HA-PIK3CA-IRES2-EGFP 
fragment was cloned into a recombination-mediated cassette exchange (RMCE) plasmid. The 
vector was introduced into the modified Rosa26 locus of Balb/c mouse embryonic stem (ES) 
cells by RMCE and the ES cells used for blastocyst injection (Tchorz, Kinter et al. 2009). Chimeric 
mice were mated with Balb/c mice and transgenic mice identified by genotyping using the 
primers 5’-TGGCCAGTACCTCATGGATT-3’ and 5’-GCAATACATCTGGGCTACTTCAT-3’. FVB/N-
Tg(MMTV-Cre) and FVB/N.B6-Tg(WAPiCre) mice were described previously (Wintermantel, 
Mayer et al. 2002; Andrechek, White et al. 2005). Tg(MMTV-Cre) mice are in the FVB/N 
background and B6-Tg(WAPiCre) mice were backcrossed for five generations to an FVB/N 
background. MMTV-NeuNT (strain TG.NK) mice were purchased from Charles River 
(Wilmington, MA). 
 
Immunohistochemistry 
The following antibodies were used: K14 (Thermo Scientific, RB-9020, 1:1000), K18 (Fitzgerald, 
#GP11, 1:500), GFP (Invitrogen, A11122, 1:500), ER (Santa Cruz, SC-542, 1:1000), PR (Thermo 
Scientific, RM-9102, 1:200), α-SMA (Thermo Scientific, RB-9010, 1:500), cleaved caspase-3 (Cell 
Signaling, #9661, 1:100), and Ki-67 (Thermo Scientific, RM-9106, 1:1000). 
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Protein Analysis 
Mouse tumors were lysed in a modified RIPA buffer [50mmol/L Tris-HCl (pH 7.5); 1% NP40; 150 
mmol/L NaCl; 0.5% sodium deoxycholate; 0.1% SDS; 5 mmol/L EGTA; 2 mmol/L 
phenylmethylsulfonyl fluoride; 2 μg/mL each of aprotinin, leupeptin, and pepstatin; 2 mmol/L 
Na3VO4; 10mmol/L NaF; 10mmol/L β-glycerophosphate; 10mmol/L sodium pyrophosphate]. For 
immunoprecipitation, samples were lysed in Co-IP buffer [25mM Tris-HCl (pH 7.5); 2.5mM 
EGTA; 75mM NaCl; 0.75mM MgCl2; 12.5mM β-glycerophosphate; 12.5mM NaF]. Antibodies 
were purchased from Cell Signaling except for α-GFP (MBL), α-K14 (Thermo Scientific), and α-
HA (Covance). 
 
Statistical analysis 
Survival curves were generated using the Kaplan-Meier method with the software StatView. 
 
Southern Blot 
12 μg of genomic DNA isolated from mouse tails were digested with a total of 8 U of AvrII 
enzyme (New England Biolabs) and separated on a 1% Agarose gel. A DIG-labeled DNA probe 
targeting the neomycin resistance cassette was amplified using the PCR DIG Probe Synthesis Kit 
(Roche) and the primers ATGGGATCGGCCATTGAACAAGAT and CGGCCATTTTCCACCATGATAT. 
 
RT-PCR 
RNA was isolated from 100-200 mg of mouse tissue using Trizol (Invitrogen) according to the 
manufacturer’s protocol. Traces of contaminating DNA were removed by a 30 minutes 
incubation of 5μg of RNA with TURBO DNase (Ambion) at 37°C and RT-PCR performed using the 
ThermoScript RT-PCR System (Invitrogen). Taq Man polymerase and appropriate buffers were 
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purchased from New England Biolabs. Human PIK3CA was detected using the primers 
CAGATCCCAGTGTGGTGGTACG and CCTCACGGAGGCATTCTAAAGT and endogenous gapdh was 
detected using the primers CATCAAGAAGGTGGTGAAGC and GGGAGTTGCTGTTGAAGTCG. 
 
MEC isolation and mammosphere assay 
Mammary glands were isolated from mice and chopped into fine pieces using a razor blade. The 
pieces were digested on a rotor shaker at 37 degrees in a solution containing DMEM-F12 
medium (Gibco), collagenase *300 U/ml+, hyualuronidase *100 U/ml+, insulin *10μg/ml+, 
hydrocortisone *0.5μg/ml+, β-mercaptoethanol (1:250’000), and antibiotics (penicillin and 
streptomycin) for 2-3 hours. The resulting organoid suspension was incubated with red blood 
cell lysis buffer to remove erythrocytes. After washing with PBS, organoids were incubated for 
5-10 minutes with HiQtase at 37 degrees and pipetted up and down extensively to produce 
single cells. After washing with 2% fetal calf serum FBS the cells were resuspended in 
suspension medium consisting of DMEM-F12 medium, 1X B27 supplement (Invitrogen), 
recombinant FGF [20ng/ml], mouse EGF [20ng/ml], and gentamycin [100 μg/ml+ and filtered 
through a 40 μm cell strainer. 5’000 cells were seeded in 0.5 ml of suspension medium into 
wells of a 24-well dish. For passaging spheres were collected and digested in 0.05% Trypsin 
solution at 37 degrees for 5 minutes. Cells were resuspended in suspension medium, filtered 
through a 40 μm cell strainer, and were counted before seeding as single cells analogue to first 
passage. 
 
FACS analysis 
Isolation of MECs was performed according to the protocol of Sleeman and co-workers 
(Sleeman, Kendrick et al. 2006) with the exception of the antibody that was used to stain CD24. 
We used a PerCP/Cy5.5-labeled anti-mouse CD24 antibody (Biolegend, #101823, 1:33).
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